Turning Point Therapeutics Inc - ESG Rating & Company Profile powered by AI
The analysis of Turning Point Therapeutics Inc is prepared by All Street Sevva using cutting edge Cognitive Robots. Browse to the end of this webpage for potential risks for Turning Point Therapeutics Inc based on sector, location and marketcap. This Disclosure score covers 17 UN SDGs including: 'Zero Hunger', 'Industry, Innovation & Infrastructure' and 'Life below Water'.
Turning Point Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.1; made up of an environmental score of 1.3, social score of 1.1 and governance score of 4.0.
2.1
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1551 | Voyager Life PLC | 2.2 | Medium |
1551 | Source Natural Foods and Herbal Supplements Ltd | 2.2 | Medium |
1571 | Turning Point Therapeutics Inc | 2.1 | Medium |
1571 | Cerevel Therapeutics Holdings Inc | 2.1 | Medium |
1571 | Charlotte's Web Holdings Inc | 2.1 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Turning Point Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Turning Point Therapeutics Inc disclose current and historical energy intensity?
Does Turning Point Therapeutics Inc report the average age of the workforce?
Does Turning Point Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Turning Point Therapeutics Inc disclose its ethnicity pay gap?
Does Turning Point Therapeutics Inc disclose cybersecurity risks?
Does Turning Point Therapeutics Inc offer flexible work?
Does Turning Point Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Turning Point Therapeutics Inc disclose the number of employees in R&D functions?
Does Turning Point Therapeutics Inc conduct supply chain audits?
Does Turning Point Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Turning Point Therapeutics Inc conduct 360 degree staff reviews?
Does Turning Point Therapeutics Inc disclose the individual responsible for D&I?
Does Turning Point Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Turning Point Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Turning Point Therapeutics Inc disclose water use targets?
Does Turning Point Therapeutics Inc have careers partnerships with academic institutions?
Did Turning Point Therapeutics Inc have a product recall in the last two years?
Does Turning Point Therapeutics Inc disclose incidents of discrimination?
Does Turning Point Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Turning Point Therapeutics Inc issued a profit warning in the past 24 months?
Does Turning Point Therapeutics Inc disclose parental leave metrics?
Does Turning Point Therapeutics Inc disclose climate scenario or pathway analysis?
Does Turning Point Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Turning Point Therapeutics Inc disclose the pay ratio of women to men?
Does Turning Point Therapeutics Inc support suppliers with sustainability related research and development?
Does Turning Point Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Turning Point Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Turning Point Therapeutics Inc involved in embryonic stem cell research?
Does Turning Point Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Turning Point Therapeutics Inc disclose its waste policy?
Does Turning Point Therapeutics Inc report according to TCFD requirements?
Does Turning Point Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Turning Point Therapeutics Inc disclose energy use targets?
Does Turning Point Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Turning Point Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Turning Point Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0022, a MET/CSF1R/SRC inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in Phase 1/2 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, a preclinical ALK inhibitor for advanced non-small-cell lung cancer. The company was founded in 2013 and is headquartered in San Diego, California.